论文部分内容阅读
目的比较复方二甲双胍格列美脲片与单方格列美脲片中的格列美脲在Beagle犬体内的药物动力学差异。方法6只Beagle随机分为2组,犬单剂量口服单方格列美脲片和复方二甲双胍格列美脲片后,利用LC-MS/MS法分析血浆中格列美脲的浓度。采用DAS 2.1.1软件对主要药物动力学参数进行计算,并用SPSS 16.0软件对其进行配对t检验和非参数检验。结果Beagle犬单剂量口服单方格列美脲片与复方二甲双胍格列美脲片的主要药物动力学参数如下:ρmax分别为(1 722.9±237.8)和(1 860.6±315.2)μg·L-1,tmax分别为(3.3±0.3)和(3.2±0.3)h,AUC0→t分别为(12 456.9±31 93.6)和(12 048.1±3 577.8)μg·h·L-1,AUC0→∞分别为(12 578.4±3 167.2)和(12 330.4±3 756.8)μg·h·L-1。经统计学检验,各药物动力学参数间无显著性差异(P>0.05)。结论复方二甲双胍格列美脲片中的格列美脲在Beagle犬体内的药物动力学过程与单方相比无显著差异。
Objective To compare the pharmacokinetics of glimepiride in the combination of metformin and glipizide in Beagle dogs. Methods Six Beagle rats were randomly divided into two groups. The dogs were given oral single-dose glibenclamide tablets and metformin compound glipizide tablets. The concentrations of glimepiride in plasma were analyzed by LC-MS / MS. The main pharmacokinetic parameters were calculated using DAS 2.1.1 software and paired t-test and nonparametric test were performed with SPSS 16.0 software. Results The main pharmacokinetic parameters of Beagle dog single dose oral mongliotrin and metformin glimepiride tablets were as follows: ρmax were (1 722.9 ± 237.8) and (1860.6 ± 315.2) μg · L -1 , tmax were (3.3 ± 0.3) and (3.2 ± 0.3) h, AUC0 → t were (12 456.9 ± 31 93.6) and (12 048.1 ± 3577.8) μg · h · L-1, respectively. AUC0 → ∞ were (12 578.4 ± 3 167.2) and (12 330.4 ± 3 756.8) μg · h · L -1, respectively. Statistically, there was no significant difference between the pharmacokinetic parameters (P> 0.05). Conclusion The pharmacokinetics of glimepiride in compound metformin glipizide tablets in Beagle dogs were not significantly different from those in unilateral formula.